Pharmalot… Pharmalittle… Trick Or Treat
1 CommentBy Ed Silverman // October 31st, 2008 // 7:10 am
Decisions, decisions. What will you be this Halloween? A sales rep? A cardiologist? A brand manager? Maybe a cost-cutting consultant? How about a compliance officer? Whatever your fancy, here are a few items to peruse while you mull this over…
Erbitux Gets Priority FDA Review For Broader Use (The Wall Street Journal)
AstraZeneca Posts Strong Sales Gain (The Financial Times)
Sanofi Raises Guidance While Profits Rise Slightly (Yahoo/Reuters)
Novo Nordisk May Spend $2 Billion On Acquisitions (Bloomberg News)
Biogen & Genentech Develop Blood Cancer Drug (Reuters)
Mylan Profit Jumps On Blood Pressure Drug (Bloomberg News)
Vanda Pharmaceuticals Halts Development (Washington Business Journal)
Anon
It’s too bad the FDA reviewer who turned down Vanda’s Iloperidone was then forced out of her position.